MedPath

Risk Factors for Occurrence of Placenta Accrete Spectrum Following Primary Cesarean Delivery

Completed
Conditions
Placenta Accreta
Registration Number
NCT04264169
Lead Sponsor
Mansoura University Hospital
Brief Summary

This study will be conducted on a group of patients undergoing repeat elective caesarean delivery attending at Mansoura university hospital.

- This study will investigate patients' attending to the antenatal care clinic for elective termination of pregnancy with history of previous one caesarean delivery in the period between (January 2020 till January 2021).

Detailed Description

Participants in this study will be a group of patients with past history of previous one caesarean delivery and attending for elective termination of the current pregnancy.

Patients data will be collected and analysed as following:

* Personal data: Age, residency, job, special habits, BMI

* Past obstetric history:

Gravidity, parity, full term normal delivery, full term assisted vaginal deliveries, preterm, stillbirth, abortion, previous pregnancy complication and complication during puerperium • Previous delivery: Indication, duration, place of delivery, results of delivery, complication during labour, complication during puerperium

* Past medical, surgical or gynaecological history

* Pregnancy by assisted reproductive techniques

* Current pregnancy complications

* Trans abdominal and trans vaginal ultrasound examination Patients will be considered to have placenta praevia if the lower edge of the placenta is less than 2 cm form the internal os of the cervix

Placenta accreta will be considered as the following(7, 8) (Placental lacunae, Loss of hypoechoic space, Abnormalities of uterus-bladder interface, Color Doppler abnormalities)

2D grey-scale Loss of the "clear zone" Loss or irregularity of the hypoechoic plane in the myometrium underneath the placental bed (the "clear zone") Abnormal placental lacunae Presence of numerous lacunae including some that are large and irregular (Fin berg grade 3) often containing turbulent flow visible in grey-scale imaging Bladder wall interruption Loss or interruption of the bright bladder wall (the hyperechoic band or "line" between the uterine serosa and the bladder lumen) Myometrial thinning Thinning of the myometrium overlying the placenta to \<1 mm or undetectable Placental bulge Deviation of the uterine serosa away from the expected plane, caused by an abnormal bulge of placental tissue into a neighbouring organ, typically the bladder. The uterine serosa appears intact but the outline shape is distorted Focal exophytic mass Placental tissue seen breaking through the uterine serosa and extending beyond it. Most often seen inside a filled urinary bladder Color Doppler imaging Uterovesical hypervascularity Striking amount of colour Doppler signal seen between the myometrium and the posterior wall of the bladder. This sign probably indicates numerous, closely packed, tortuous vessels in that region (demonstrating multi-directional flow and aliasing artifact) Subplacental hypervascularity Striking amount of color Doppler signal seen in the placental bed. This sign probably indicates numerous,closely packed, tortuous vessels in that region (demonstrating multidirectional flow and aliasing artifact)

Bridging vessels Vessels appearing to extend from the placenta across the myometrium and beyond the serosa into the bladder or other organs. Often running perpendicular to the myometrium

Placental lacunae feeder vessels Vessels with high velocity blood flow leading from the myometrium into the placental lacunae, causing turbulence upon entry

At laparotomy the following data will be reviewed(6):

Grade 1: Abnormally adherent placenta (placenta adherenta or accreta)

* Macroscopically, the uterus shows no obvious distension over the placental bed (placental "bulge"), no placental tissue is seen invading through the surface of the uterus, and there is no or minimal neovascularity Grade 2: Abnormally invasive placenta (Increta)

* Abnormal macroscopic findings over the placental bed: bluish/purple colouring, distension (placental "bulge")

* Significant amounts of hypervascularity (dense tangled bed of vessels or multiple vessels running parallel craniocaudially in the uterine serosa)

* No placental tissue seen to be invading through the uterine serosa.

* Gentle cord traction results in the uterus being pulled inwards without separation of the placenta (so-called the dimple sign) Histologic criteria

* Hysterectomy specimen or partial myometrial resection of the increta area shows placental villi within the muscular fibers and sometimes in the lumen of the deep uterine vasculature (radial or arcuate arteries) Grade 3: Abnormally invasive placenta (Percreta) Grade 3a: Limited to the uterine serosa Clinical criteria

* At laparotomy

* Abnormal macroscopic findings on uterine serosal surface (as above) and placental tissue seen to be invading through the surface of the uterus

* No invasion into any other organ, including the posterior wall of the bladder (a clear surgical plane can be identified between the bladder and uterus)

• Histologic criteria

* Hysterectomy specimen showing villous tissue within or breaching the uterine serosa Grade 3b: With urinary bladder invasion Clinical criteria

• At laparotomy

* Placental villi are seen to be invading into the bladder but no other organs

* Clear surgical plane cannot be identified between the bladder and uterus Histologic criteria

* Hysterectomy specimen showing villous tissue breaching the uterine serosa and invading the bladder wall tissue or urothelium Grade 3c: With invasion of other pelvic tissue/organs Clinical criteria

* At laparotomy

* Placental villi are seen to be invading into the broad ligament, vaginal wall, pelvic sidewall or any other pelvic organ (with or without invasion of the bladder) Histologic criteria • Hysterectomy specimen showing villous tissue breaching the uterine serosa and invading pelvic tissues/organs (with or without invasion of the bladder) .For the purposes of this classification, "uterus" includes the uterine body and uterine cervix .

* The data will be analysed after putting it in the following groups,

* study group consisted of patients with placenta praevia diagnosed by TVUS, control group consisted of patients undergoing elective caesarean delivery without having placenta praevia by transvaginal ultrasound (TVUS) examination

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Patients with history of previous one caesarean delivery
  • Patients who refused trail of vaginal birth after caesarean section
  • Patients with permanent indication for caesarean section like contracted pelvis
  • Patient without any history of medical diseases
Exclusion Criteria
  • Patients with history of more than one previous caesarean delivery
  • Patients with medical disorders complicating pregnancy kike preeclampsia and gestational diabetes mellitus
  • Patients with known uterine abnormalities eg (Bicornuate uterus, Adenomyosis, Submucous fibroids and Myotonic dystrophy)
  • Patients who are candidates for vaginal birth after caesarean section

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
association between indication of primary Cesarean delivery and degree of severity of placenta accreta spectrum1 day

association between indication of primary Cesarean delivery and degree of severity of placenta accreta spectrum

Secondary Outcome Measures
NameTimeMethod
the association between parity, gravidity, place of the primary Cesarean delivery, assisted conception, and vaginal delivery before and after the primary Cesarean delivery,postpartum complications and degree of placenta accreta spectrum1 week

the association between parity, gravidity, place of the primary Cesarean delivery, assisted conception, and vaginal delivery before and after the primary Cesarean delivery ,postpartum complications and degree of placenta accreta spectrum

Trial Locations

Locations (1)

Faculty of Medicine

🇪🇬

Mansoura, Dakahlia, Egypt

© Copyright 2025. All Rights Reserved by MedPath